33.6 C
Delhi
Sunday, August 31, 2025

Dr Reddy Labs launches Lenalidomide Capsules in US

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Dr. Reddy’s Labs on Thursday announced the launch of Lenalidomide Capsules in the US market, , a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA).

With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

‘We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

“Bringing a more affordable generic version to market creates greater patient access for this important drug.’

Dr. Reddy’s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.

Related articles

Self-reliance in Defence is not merely an option, but a condition for survival & progress: Rajnath Singh

New Delhi: Defence Minister Rajnath Singh said that in today’s era of terrorism, pandemics and regional conflicts, self-reliance...

Putin advocates reforms in UN, IMF to reflect modern realities

Moscow/Beijing: Russian President Vladmir Putin, ahead of the upcoming SCO summit in the Chinese city of Tianjin, lauded...

India’s GDP surges 7.8 pc in Q1 FY 26, led by services and manufacturing

New Delhi: India’s economy sprinted ahead in the first quarter of FY 2025-26, with real Gross Domestic Product...

India crush Nepal 5-0 to clinch SAFF U17 Women’s Championship 2025 title

New Delhi/Thimphu: India’s dominance in South Asian football continued as the U 17 women’s team thrashed Nepal 5-0...